Saira Khan1, Jianwen Cai2, Matthew E Nielsen3,4,5, Melissa A Troester3,5, James L Mohler4,5,6,7, Elizabeth T H Fontham8, Laura Farnan5, Bettina F Drake9, Andrew F Olshan3,5, Jeannette T Bensen3,5. 1. Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, 660 S. Euclid Avenue, Campus Box 8100, St. Louis, MO, 63110, USA. khans@wustl.edu. 2. Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina-Chapel Hill, 135 Dauer Drive, Chapel Hill, NC, 27599, USA. 3. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina-Chapel Hill, 135 Dauer Drive, Chapel Hill, NC, 27599, USA. 4. Department of Urology, School of Medicine, University of North Carolina-Chapel Hill, 170 Manning Dr., Chapel Hill, NC, 27599, USA. 5. Lineberger Comprehensive Cancer Center, School of Medicine, University of North Carolina-Chapel Hill, 450 West Drive, Chapel Hill, NC, 27599, USA. 6. Department of Urology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY, 14263, USA. 7. Department of Urology, University of Buffalo School of Medicine and Biotechnology, 100 High Street, Buffalo, NY, 14203, USA. 8. School of Public Health, Louisiana State University Health Science Center, 2020 Gravier Street, New Orleans, LA, 70112, USA. 9. Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis School of Medicine, 660 S. Euclid Avenue, Campus Box 8100, St. Louis, MO, 63110, USA.
Abstract
PURPOSE: Metformin has been associated with a reduced incidence of prostate cancer and improved prostate cancer outcomes. However, whether race modifies the association between metformin use and prostate cancer aggressiveness remains uncertain. The association between metformin use and prostate cancer aggressiveness was examined separately in Black Americans (Blacks) and White Americans (Whites). METHODS: The study population consisted of 305 Black and 195 White research participants with incident prostate cancer and self-reported diabetes from the North Carolina-Louisiana Prostate Cancer Project. High-aggressive prostate cancer was defined using a composite measure of Gleason sum, prostate-specific antigen, and clinical stage. Multivariable logistic regression was used to assess the association between metformin use and high-aggressive prostate cancer at diagnosis, separately among Whites and Blacks, with adjustment for age, screening history, site, education, insurance, and body mass index. RESULTS: Metformin use was associated positively with high-aggressive prostate cancer in Blacks (OR 2.01; 95% CI 1.05, 3.83). By contrast, a weak inverse association between metformin use and high-aggressive prostate cancer was found in Whites (OR 0.80, 95% CI 0.34, 1.85). CONCLUSIONS: The association between metformin use and prostate cancer aggressiveness may be modified by race.
PURPOSE:Metformin has been associated with a reduced incidence of prostate cancer and improved prostate cancer outcomes. However, whether race modifies the association between metformin use and prostate cancer aggressiveness remains uncertain. The association between metformin use and prostate cancer aggressiveness was examined separately in Black Americans (Blacks) and White Americans (Whites). METHODS: The study population consisted of 305 Black and 195 White research participants with incident prostate cancer and self-reported diabetes from the North Carolina-Louisiana Prostate Cancer Project. High-aggressive prostate cancer was defined using a composite measure of Gleason sum, prostate-specific antigen, and clinical stage. Multivariable logistic regression was used to assess the association between metformin use and high-aggressive prostate cancer at diagnosis, separately among Whites and Blacks, with adjustment for age, screening history, site, education, insurance, and body mass index. RESULTS:Metformin use was associated positively with high-aggressive prostate cancer in Blacks (OR 2.01; 95% CI 1.05, 3.83). By contrast, a weak inverse association between metformin use and high-aggressive prostate cancer was found in Whites (OR 0.80, 95% CI 0.34, 1.85). CONCLUSIONS: The association between metformin use and prostate cancer aggressiveness may be modified by race.
Entities:
Keywords:
Aggressiveness; Black Americans; Metformin; PCaP; Prostate cancer
Authors: Saira Khan; Jianwen Cai; Matthew E Nielsen; Melissa A Troester; James L Mohler; Elizabeth T H Fontham; Laura H Hendrix; Laura Farnan; Andrew F Olshan; Jeannette T Bensen Journal: Prostate Date: 2017-03-06 Impact factor: 4.104
Authors: David Margel; David Urbach; Lorraine L Lipscombe; Chaim M Bell; Girish Kulkarni; Peter C Austin; Neil Fleshner Journal: J Natl Cancer Inst Date: 2013-07-13 Impact factor: 13.506
Authors: Richard W Grant; Deborah J Wexler; Alice J Watson; William T Lester; Enrico Cagliero; Eric G Campbell; David M Nathan Journal: Diabetes Care Date: 2007-03-02 Impact factor: 19.112
Authors: Demetrius Albanes; Stephanie J Weinstein; Margaret E Wright; Satu Männistö; Paul J Limburg; Kirk Snyder; Jarmo Virtamo Journal: J Natl Cancer Inst Date: 2009-08-21 Impact factor: 13.506
Authors: Lisa Scarton; Ara Jo; Zhigang Xie; LaToya J O'Neal; Juan M Munoz Pena; Thomas J George; Jiang Bian Journal: PLoS One Date: 2022-10-19 Impact factor: 3.752
Authors: Enrique Gómez-Gómez; Julia Carrasco-Valiente; Juan Pablo Campos-Hernández; Ana Maria Blanca-Pedregosa; Juan Manuel Jiménez-Vacas; Jesus Ruiz-García; Jose Valero-Rosa; Raul Miguel Luque; María José Requena-Tapia Journal: J Cell Mol Med Date: 2018-11-18 Impact factor: 5.310